Based on the Extrawell Pharmaceutical Holdings Ltd stock forecast from 0 analysts, the average analyst target price for Extrawell Pharmaceutical Holdings Ltd is not available over the next 12 months. Extrawell Pharmaceutical Holdings Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Extrawell Pharmaceutical Holdings Ltd is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Extrawell Pharmaceutical Holdings Ltd’s stock price was HKD 0.027. Extrawell Pharmaceutical Holdings Ltd’s stock price has changed by -3.57% over the past week, -10.00% over the past month and -57.81% over the last year.
No recent analyst target price found for Extrawell Pharmaceutical Holdings Ltd
No recent average analyst rating found for Extrawell Pharmaceutical Holdings Ltd
Company Overview Extrawell Pharmaceutical Holdings Ltd
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China and Hong Kong. The company operates through Manufacturing, Trading, and Gene Development segments. It manufactures transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing; and ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. The company also involves in marketing and distribution of imported pharmaceutical products, including Skin-Cap for the treatment of itching, irritation, redness, and scaly skin issues and Millibar for the treatment of high blood pressure. In addition, it develops oral insulin product, which is in clinical trial stage for the treatment of diabetes. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited was incorporated in 1998 and is headquartered in Quarry Bay, Hong Kong. Read Less
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China and Hong Kong. The company operates through Manufacturing, Trading, and Gene Development seg...Read More
Frequently Asked Questions About Extrawell Pharmaceutical Holdings Ltd (0858:HK) Stock
Stock Target Advisor's fundamental analysis for Extrawell Pharmaceutical Holdings Ltd's stock is Slightly Bearish.
Unfortunately we do not have enough data on 0858:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 0858:HK's stock to indicate what its average analyst target is.
0858:HK stock's Price/Earning ratio is 0.98.
Our analysis grades 0858:HK stock's Price / Earning ratio at A+. This means that 0858:HK stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 0858:HK may be undervalued for its sector.
The last closing price of 0858:HK's stock was HKD 0.03.
The most recent market capitalization for 0858:HK is HKD 0.07B.
Unfortunately we do not have enough analyst data on 0858:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Extrawell Pharmaceutical Holdings Ltd's stock.
As per our most recent records Extrawell Pharmaceutical Holdings Ltd has 169 Employees.
Extrawell Pharmaceutical Holdings Ltd's registered address is Devon House, Quarry Bay, Hong Kong.
You can get more information about it from Extrawell Pharmaceutical Holdings Ltd's website at https://www.extrawell.com.hk.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0858:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
